✦ LIBER ✦

Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naïve patients with chronic hepatitis C genotype 1 infection

✍ Scribed by Peter Ferenci; Elisabeth Formann; Hermann Laferl; Michael Gschwantler; Franz Hackl; Harald Brunner; Rainer Hubmann; Christian Datz; Rudolf Stauber; Petra Steindl-Munda; Harald H. Kessler; Anton Klingler; Alfred Gangl; for the Austrian Hepatitis Study Group

Book ID: 116650914
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 182 KB
Volume: 44
Category: Article
ISSN: 0168-8278
DOI: 10.1016/j.jhep.2005.09.015

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Peginterferon alfa-2b plus ribavirin for

Peginterferon alfa-2b plus ribavirin for naïve patients with genotype 1 chronic hepatitis C: a randomized controlled trial

✍ Savino Bruno; Calogero Cammà; Vito Di Marco; Mariagrazia Rumi; Maria Vinci; Mari 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 373 KB

PEG-IFN alfa-2a (40kd) (Pegasys) plus am

PEG-IFN alfa-2a (40kd) (Pegasys) plus amantadine (AMA) or ribavirin (RBV) in naïve patients with chronic hepatitis C (CHC)

✍ G. Ideo; A. Attili; G. Ruggiero; A. Craxi; G. Di Perri; A. Mangia; A. Picciotto; 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 154 KB

Treatment of insulin resistance with met

Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin

✍ Manuel Romero-Gómez; Moisés Diago; Raúl J. Andrade; José L. Calleja; Javier Salm 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 309 KB 👁 1 views

Insulin resistance affects sustained virological response (SVR) in chronic hepatitis C. To know whether adding metformin to standard antiviral treatment improves SVR, we conducted a prospective, multicentered, randomized, double-blinded, placebo-controlled trial in 19 Spanish hospitals, including 12

Clinical trial: a randomized trial of pe

Clinical trial: a randomized trial of pegylated-interferon-α-2a plus ribavirin with or without amantadine in treatment-naïve or relapsing chronic hepatitis C patients

✍ P. LANGLET; F. D’HEYGERE; J. HENRION; M. ADLER; J. DELWAIDE; H. VAN VLIERBERGHE; 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 134 KB

A randomized controlled trial of pegylat

A randomized controlled trial of pegylated interferon α-2a (40 KD) or interferon α-2a plus ribavirin and amantadine vs interferon α-2a and ribavirin in treatment-naïve patients with chronic hepatitis C

✍ A. Mangia; G. L. Ricci; M. Persico; N. Minerva; V. Carretta; D. Bacca; M. Cela; 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 134 KB

522 Combination therapy with peginterfer

522 Combination therapy with peginterferon alfa-2A (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in treatment-naive patients with chronic hepatitis C and genotype 1 infection: Individual estimated probability of sustained virological response (SVR)

✍ O. Weiland; M.W. Fried; S.J. Hadziyannis; G.R. Foster; D. Messinger; K. Freivoge 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 62 KB